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Abstract
Pancreatic cancer (PaCa) is one of the most lethal cancers, with an estimated 5-year survival of ,5% even when patients are
given the best treatment available. In addition, these treatments are often toxic and expensive, thus new agents which are
safe, affordable and effective are urgently needed. We describe here the results of our study with acetyl-11-keto-b-boswellic
acid (AKBA), an agent obtained from an Ayurvedic medicine, gum resin of Boswellia serrata. Whether AKBA has an activity
against human PaCa, was examined in in vitro models and in an orthotopic nude mouse model of PaCa. We found that
AKBA inhibited the proliferation of four different PaCa cell lines (AsPC-1, PANC-28, and MIA PaCa-2 with K-Ras and p53
mutations, and BxPC-3 with wild-type K-Ras and p53 mutation). These effects correlated with an inhibition of constitutively
active NF-kB and suppression of NF-kB regulating gene expression. AKBA also induced apoptosis, and sensitized the cells to
apoptotic effects of gemcitabine. In the orthotopic nude mouse model of PaCa, p.o. administration of AKBA alone (100 mg/
kg) significantly inhibited the tumor growth; this activity was enhanced by gemcitabine. In addition, AKBA inhibited the
metastasis of the PaCa to spleen, liver, and lungs. This correlated with decreases in Ki-67, a biomarker of proliferation, and
CD31, a biomarker of microvessel density, in the tumor tissue. AKBA produced significant decreases in the expression of NF-
kB regulating genes in the tissues. Immunohistochemical analysis also showed AKBA downregulated the expression of COX-
2, MMP-9, CXCR4, and VEGF in the tissues. Overall these results demonstrate that AKBA can suppress the growth and
metastasis of human pancreatic tumors in an orthotopic nude mouse model that correlates with modulation of multiple
targets.
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Introduction
The National Cancer Institute estimated that 18,770 men and
18,030 women in the United States would die of pancreatic cancer
(PaCa) in 2010 [1]. Because of a lack of early detection methods
and an absence of effective biomarkers, patients with PaCa are
usually diagnosed at a late stage, by which time the 5-year survival
rate is less than 5% [2]. This low survival rate emphasizes the
increased need for effective chemopreventive strategies, early
detection methods, and novel treatments. Only 12% of the
patients have partial or complete responses to gemcitabine, the
standard treatment for advanced PaCa [3], and this treatment is
associated with multiple adverse events and drug resistance.
Erlotinib, also approved by the U.S. Food and Drug Administra-
tion (FDA) to treat pancreatic cancer, does not show significant
efficacy either. Thus novel agents that are safe, inexpensive and
effective are needed for the treatment of this disease.
One potential source of novel agents is the large pharmacopeia
of traditional medicines. One with promise in the treatment of
PaCa is the AKBA (acetyl-11-keto-b-boswellic acid), obtained
from the medicinal plant Boswellia serrata. It contains beta boswellic
acid, a pentacyclic triterpene and the active component of the gum
resin (also called frankincense in European pharmacopeia)
secreted by the bark of the tree Boswellia serrata (Sallai guggul)
[4].
AKBA has been used for centuries in traditional Ayurvedic
medicine for a wide variety of inflammatory diseases, including
inflammatory bowel disease [5] and rheumatoid arthritis [6].
AKBA has been shown to inhibit the growth of a wide variety of
tumor cells including glioma [7], colon cancer [8,9,10], leukemia
cells [11,12,13,14,15], human melanoma [16], hepatoma [8], and
prostate cancer cells [17]. It has been also reported that AKBA has
apoptotic effects through a wide variety of mechanisms. AKBA
inhibits topoisomerase I and II without inhibiting DNA fragmen-
tation [7,13], and induces death receptor (DR)-5 but not DR-4 or
Fas through increased expression levels of CAAT/enhancer
binding protein homologous protein (CHOP), which led to the
activation of caspase-8 in prostate cancer cells [18]. The anti-
inflammatory effects of this agent were further demonstrated by
studies that showed that LPS-induced TNF production is blocked
by this drug [19]. Anti-proliferative and anti-inflammatory effects
of AKBA are also mediated through the suppression of the NF-kB
pathway [20] and STAT3 pathway [21]. More recently our
laboratory showed that AKBA can downregulate the expression of
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invasion of various cancers [22]. All these studies suggest an anti-
inflammatory and anticancer potential for AKBA.
Because several of these targets play a critical role in growth and
metastasis of PaCa, we decided to measure the effects of AKBA on
a panel of PaCa cell lines and determine whether AKBA alone or
in combination with gemcitabine, the current standard of care,
affects the growth and metastasis of human pancreatic tumors in
nude mice. We found that AKBA inhibited the proliferation and
enhanced the apoptosis of gemcitabine in four PaCa cell lines.
Moreover, it suppressed the growth and metastasis of human
pancreatic tumors in an orthotopic nude mouse model through
modulation of multiple targets.
Results
AKBA inhibits the proliferation of pancreatic cancer cells
in vitro
We first examined whether AKBA could inhibit the proliferation
of human PaCa cell lines. We treated these cell lines with different
doses of AKBA for various time periods and determined the
inhibitionofproliferationbyexaminingmitochondrialactivityusing
the MTT uptake method. As Fig. 1A shows, AKBA suppressed the
proliferation of all four pancreatic cancer cell lines in a dose- and
time-dependent manner. BxPC-3 was most sensitive as 25 mmol/L
inhibited proliferation, whereas for the other cell lines, a 50 mmol/L
dose was required to fully suppress proliferation.
AKBA inhibits constitutive NF-kB activation and
NF-kB-regulated proteins in pancreatic cancer cells
We next determined how AKBA inhibits proliferation. Because
NF-kB has been linked with proliferation, we examined AKBA’s
ability to inhibit constitutive NF-kB activation in PANC-28 cell
lines. Our results showed that AKBA inhibited constitutive NF-kB
activation in PANC-28 (Fig. 1B). We next examined whether
AKBA modulates the NF-kB-regulated gene products linked to
survival, proliferation, invasion, and angiogenesis. As shown in
Figure 1C, AKBA downregulated the expression of antiapoptotic
(Bcl-2, Bcl-xL, and survivin), proliferative (COX-2, c-myc, and
cyclin D1), and metastatic (MMP-9, CXCR4) proteins in a dose-
dependent manner.
AKBA potentiates the apoptotic activity of gemcitabine
in pancreatic cancer cells
To determine whether AKBA could enhance the apoptotic
effects of gemcitabine in these cell lines, we performed the LIVE/
DEAD assay, which measures esterase activity. At a dose at which
AKBA (25 mmol/L) and gemcitabine (500 nmol/L) alone had
minimally apoptotic effects, the two together were highly effective
in inducing apoptosis (Fig. 1D). Again BxPC-3 was found to be
most sensitive to the combination and MiaPaCa-2 was found to be
least sensitive. AKBA also potentiated caspase-mediated cleavage
of PARP induced by gemcitabine (Fig. 1E).
AKBA inhibits the growth of human pancreatic tumors in
an orthotopic nude mice model
On basis of our in vitro results, we designed studies to determine
the effects of AKBA alone and in combination with gemcitabine in
human pancreatic tumors orthotopically implanted in nude mice
(Fig. 2A). Luciferase-transfected PANC-28 cells were implanted in
the tails of the pancreas in nude mice. On the basis of IVIS
imaging, the mice were randomized into four groups 1 week later.
The treatment was started 1 week after tumor cell implantation
and continued per experimental protocol for 4 weeks. The animals
were euthanized 6 weeks after tumor cell injection and 5 weeks
from the start of treatment. The bioluminescence imaging results
indicated a gradual increase in tumor volume in the control group
as compared with the three treatment groups (Fig. 2B). The tumor
volume in AKBA group was decreased and combination group
was significantly lower than in the group treated with AKBA or
gemcitabine alone as well as in the vehicle-treated control group
(P,0.01). On the 35th day, we euthanized the mice and measured
the tumor volume with Vernier calipers. The results were in
concordance with those from bioluminescence imaging and
showed that the combination reduced the tumor volume more
than AKBA did (P,0.01; Fig. 2C and D).
AKBA suppresses distant organ metastasis in mice
We evaluated whether AKBA alone or in combination with
gemcitabine can suppress distant organ metastasis in mice. After
sacrificing the mice, we found PaCa in the spleen, liver and lungs of
vehicle-treated mice; AKBA alone suppressed metastasis to those
organs. The combination of AKBA and gemcitabine inhibited
metastasis significantly more in these mice and in fact completely
suppressed metastasis to the lung (Fig. 3).
AKBA inhibits Ki-67 and CD31 expression
The Ki-67-positive index is used as a marker for cell
proliferation, and the CD31 index is a marker for microvessel
density. We found that AKBA and gemcitabine downregulated the
expression of these biomarkers. AKBA and gemcitabine alone
significantly downregulated the expression of Ki-67 in tumor
tissues compared with the control group (P,0.05 versus control),
and the combination of these two was significantly more effective
(Fig. 4A and B). The results also showed that combination of
AKBA and gemcitabine remarkably suppressed the expression of
CD31 when compared with the control (Fig. 4C and D).
AKBA inhibits constitutive NF-kB activation and
NF-kB–regulated biomarkers in pancreatic tumors
We next investigated whether the effects of AKBA on tumor
growth in mice were associated with the inhibition of NF-kB
activation. Fig. 5A shows that AKBA alone suppressed the
constitutive activation of NF-kB in the pancreatic tumor tissue, and
this down-modulation was enhanced in tissue obtained from animals
treated with both AKBA and gemcitabine together.
We also examined expression of various biomarkers in the tumor
tissue by western blot. As shown in Fig. 5B, AKBA significantly
downregulated the expression of proteins related to antiapoptosis
(Bcl-xL), proliferation (cyclin D1, c-myc), metastasis (CXCR4) and
invasion (MMP-9, ICAM-1). Especially, expression of Bcl-xL and
MMP-9 was reduced more by the combination than just by AKBA.
Our immunohistochemical analysis also showed that COX-2,
MMP-9, CXCR4 and VEGF expression was downregulated by
AKBA, and the combination was even more effective (Fig. 5C).
AKBA can be detected in plasma and pancreatic tumor
tissue
To determinewhether AKBA isdirectlydetectableinplasmaand
pancreatic tissue, serum and PaCa tissue levels of AKBA were
examined by HPLC. Serum levels of AKBA were determined 4 h
after oral administration of drug in mice. 454623 ng/ml of AKBA
was found in plasma and 273613 ng/ml of AKBA was found in
pancreatic tissue respectively (Fig. 6). These results indicate that
there is a strong correlation between tumor regression and the
amount of AKBA in the blood.
Effect of AKBA on Growth of Pancreatic Cancer
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26943Figure 1. AKBA inhibits proliferation of PaCa cells and enhances the apoptosis of gemcitabine in vitro. A, MTT assay results showed
dose-dependent suppression of cell proliferation in all four pancreatic cancer cell lines tested. Data are representative of three independent
experiments. B, PANC-28 (1610
6) cells were treated with AKBA (10, 25, and 50 mmol/L) for 12 h; nuclear extracts were prepared and then assayed for
NF-kB activation by EMSA. C, Western blot analysis showed that AKBA inhibited constitutive expression of NF-kB–regulated gene products that
regulate antiapoptosis, proliferation, and metastasis in pancreatic cancer cells. The MIA PaCa-2 (1610
6) cells were treated with AKBA (10, 25 and
50 mmol/L) for 24 h. Whole-cell lysates were prepared and assayed for NF-kB–regulated gene products by Western blotting. Data represent two
independent experiments. D, AKBA potentiates the apoptotic effects of gemcitabine in pancreatic cancer cells in vitro. LIVE/DEAD assay results
indicated that AKBA potentiates gemcitabine-induced cytotoxicity. Percentages are proportions of apoptotic pancreatic cancer cells. Data are
representative of two independent experiments. E, The MIA PaCa-2 (1610
6) cells were treated with AKBA (25 mmol/L) for 12 h and then gemcitabine
(500 nmol/L) was added for 24 h. Whole-cell lysates were prepared and subjected to Western blotting. Data represent two independent experiments.
doi:10.1371/journal.pone.0026943.g001
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PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26943Figure 2. AKBA potentiates the effect of gemcitabine in blocking the growth of pancreatic cancer in nude mice. A, schematic of
experimental protocol described in Materials and Methods. Group I was given corn oil (100 mL, p.o., daily), group II was given AKBA (100 mg/kg, p.o.,
daily), group III was given gemcitabine (25 mg/kg, i.p., twice weekly), and group IV was given AKBA (100 mg/kg, p.o., daily) and gemcitabine (25 mg/
kg, i.p., twice weekly; n=5). B, bioluminescence IVIS images of orthotopically implanted pancreatic tumors in live, anesthetized mice and
measurements of photons per second depicting tumor volume at various time points using live IVIS imaging at the indicated times (n=5). Points,
mean; bars, SEM. C, Necropsy photographs of mice. D, tumor volumes in mice measured on the last day of the experiment at autopsy with Vernier
calipers and calculated using the formula V=2/3pr
3 (n=5). Columns, mean; bars, SE.
doi:10.1371/journal.pone.0026943.g002
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In the present study, we investigated whether AKBA, a derivative
of boswellic acid, could enhance the antitumor activity of
gemcitabine against human PaCa. We found that AKBA was
highly effective in suppressing the proliferationof variouspancreatic
cancer cell lines, and when it was combined with gemcitabine, this
activity was further enhanced. This activity in vitro correlated with
the suppression of constitutive NF-kB activation and downregula-
tion of cell survival, proliferative, and metastatic proteins. When
examined in an orthotopic model, again AKBA was highly effective
in suppressing tumor growth. It was also quite effective in
suppressing PaCa metastasis, again in correlation with the
downregulation of various biomarkers. The effects of AKBA were
more pronounced when it was combined with gemcitabine.
Ours is the first report to suggest that AKBA can suppress the
proliferation and enhance the apoptotic effect of gemcitabine in
PaCa cell lines. Gemcitabine alone had a minimal effect on
apoptosis in these cell lines. While BxPC-3 cells have been shown to
be unaffected by gemcitabine [23], we found that they were highly
sensitive to AKBA. This difference may be because BxPC-3 harbors
wild-type K-Ras, unlike the other cell lines, in which K-Ras is
mutated. The mechanism by which AKBA potentiates the
apoptotic effects of gemcitabine may involve suppression of NF-
kB. Because NF-kB has been linked with chemoresistance [24], it is
very likely that downregulation of NF-kB by AKBA sensitized the
cells to gemcitabine. These results agree with a previous report in
which MG132, sulfasalazine, and the IkBa super-repressor
sensitized pancreatic cancer cells to gemcitabine [23]. NF-kB
silencinghasbeenshowntoinduceapoptosisand increasesensitivity
to gemcitabine in a subset of pancreatic cancer cells [25]. Similarly
genistein has been shown to sensitize prostate cancer cells to
gemcitabine through the downregulation of NF-kB [26].
In addition to these in vitro results, we found that AKBA
potentiated the antitumor effects of gemcitabine in an orthotopic
model of PaCa. Tumor growth was inhibited by almost 50% by
100 mg/kg AKBA alone, and when given in combination with
gemcitabine its inhibitory effects were even greater. How AKBA
exhibited its effects in vivo was investigated in several ways. First,
AKBA alone suppressed metastasis of PaCa to the spleen, liver,
and lungs. Further, the combination of AKBA and gemcitabine
inhibited metastasis significantly in these mice. Second, markers of
proliferation (Ki-67) and microvessel density (CD31) were
significantly decreased by AKBA. Third, analysis of NF-kBi n
pancreatic tumors showed that AKBA alone and in combination
with gemcitabine inhibited constitutive activation of NF-kB.
Fourth, immunohistochemical analysis also showed that AKBA
downregulated the expression of proinflammatory biomarker
COX-2, suppressed the expression of invasion biomarker MMP-
9 and CXCR4, and inhibited the angiogenic biomarker VEGF in
the PaCa tissues. All of these effects were further enhanced by
gemcitabine. The synergistic effects of the two agents were confirmed
by Western blot analysis. Finally, the important aspect of an agent’s
ability to suppress tumor is the bioavailability, which serves primarily
a protective regulatory function constraining diffusion across
capillaries in relation to lipid solubility and molecular weight.
For a successful chemotherapy, agent must be able to reach the
blood. AKBA shows high lipid solubility, and we detected it in
concentration of 273 ng/ml in PaCa tissues, which corresponded
to concentration of 454 ng/ml in the plasma. Thus, these data
demonstrate substantial levels of AKBA in PaCa tissue after oral
administration and confirm the bioavailability of AKBA. These
results are further correlated with the tumor volume regression
and decrease in metastases to the spleen, liver, and lungs.
Figure 3. AKBA potentiates gemcitabine to inhibit distant
organ metastasis in orthotopic PaCa nude mice. AKBA and
gemcitabine combined inhibited metastases to the spleen, liver, and
lungs. Mice were killed, and their abdomen was opened surgically, and
then the number of metastasis foci in each organ was counted.
Columns, mean; bars, SE.
doi:10.1371/journal.pone.0026943.g003
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inhibition of proliferation, inflammation and metastasis, are
related to NF-kB suppression. As we discussed above, because
NF-kB has been linked with chemoresistance we would suggest
that chemosensitization of PaCa to gemcitabine by AKBA is
through an inhibitory effect on NF-kB. Our results are consistent
with a recent report in which small hairpin RNA and
pharmacological inhibitor of TGF-b-activated kinase (TAK)-1
that activates NF-kB was used to sensitize pancreatic cancer to
gemcitabine [27]. Furthermore, it has been reported that NF-kB
targeting agent such as curcumin strongly enhanced the antitumor
efficacy of radiation [28]. So we propose that AKBA may also
sensitize the tumors to radiation therapy.
AKBA has also been shown to bind and inhibit 5-LOX,
elastase, and topoisomerase II. AKBA directly inhibits 5-LOX
with an IC50 as low as 1.5 mM [29]. Further studies have revealed
Figure 4. AKBA enhances the effect of gemcitabine to inhibit tumor cell proliferation and angiogenesis in PaCa. A, the results of an
immunohistochemical analysis of proliferation marker Ki-67 indicated that PaCa cell proliferation was inhibited in mice treated with AKBA alone and
in combination with gemcitabine. B, quantification of Ki-67 positive cells was described in Materials and Methods. Columns, mean; bars, SE. C, the
results of an immunohistochemical analysis of CD31 for microvessel density in PaCa indicated that angiogenesis was inhibited by AKBA alone and in
combination with gemcitabine. D, quantification of CD31 positive cells was described in Materials and Methods. Columns, mean; bars, SE.
doi:10.1371/journal.pone.0026943.g004
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C4 ring A, and 11-keto functions are all essential for 5-LOX
inhibitory activity [30]. Unlike other pentacyclic triterpenes,
AKBA has also been shown to inhibit leukocyte elastase with an
IC50 of 15 mM [31]. Besides 5-LOX and elastase, AKBA was also
found to bind to and inhibit topoisomerase (topo) I and II a [32].
The affinity constant (KD) of AKBA for topo I and II a were
70.6 nM and 7.6 nM, respectively. When compared with
camptothecin, amascrine or etoposide, AKBA was found to be
more potent. Although, we did not measure these proinflamma-
tory and apoptotic biomarkers, it is possible that these also play an
important role in the action of AKBA against PaCa.
Our finding that AKBA downregulated COX-2 expression in
pancreatic cancer tissue is notable, as COX-2 is overexpressed in
chronic pancreatitis [33] and in human pancreatic cancer tissue.
COX-2 expression has been associated with a lower apoptotic
index [34], increased cell proliferation [35], increased risk of
metastasis [36,37], and enhanced VEGF production, leading to
Figure 5. AKBA enhances the effect of gemcitabine against the expression of NF-kB and NF-kB–regulated gene products in
pancreatic cancer tissues. A, detection of NF-kB by DNA binding in orthotopic tumor tissue samples showed the inhibition of NF-kB by AKBA. B,
Western blot analysis showed that AKBA alone or combination with gemcitabine inhibited the expression of NF-kB–dependent genes. C,
immunohistochemical analysis of NF-kB–regulated genes (COX-2, MMP-9, CXCR4 and VEGF) in pancreatic tumor tissues from mice. Percentages
indicate positive staining for the given biomarker. Samples from three animals in each group were analyzed, and representative data are shown.
doi:10.1371/journal.pone.0026943.g005
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COX-2 expression in the nude mouse implies that anti-
inflammatory effect of AKBA contributes to its anti-tumor effects.
Overall, our results show for the first time that AKBA
potentiates the antitumor activity of gemcitabine by modulating
multiple biomarkers, leading to the inhibition of proliferation,
angiogenesis, invasion, and metastasis. Several clinical trials have
been done with AKBA indicating that it is safe agent to use in
humans [40,41]. Our work presented here further provides the
basis for clinical trial in patients with pancreatic cancer, one of the
most lethal cancers known to mankind.
Ethics Statement
Our experimental protocol was reviewed and approved by the
International Animal Care and Use Committee at University of
Texas MD Anderson Cancer Center. Our IACUC protocol
number for pancreatic cancer is 10–05–11032.
Materials and Methods
Materials
Purified AKBA was supplied by Sabinsa Corp. A 50 mmol/L
stock solution of AKBA was prepared and then stored at 220uCa s
small aliquots until needed. Polyclonal antibodies against cyclin D1,
matrix metalloproteinase 9 (MMP-9), survivin, COX-2, c-Myc, Bcl-
2, and Bcl-xL were obtained from Santa Cruz Biotechnology. A
rabbit polyclonal antibody to CXCR4 was obtained from Abcam.
Anti-XIAP antibody was obtained from BD Biosciences. Anti-
obodies against VEGF and Ki-67 were purchased from Thermo
Fisher Scientific. The liquid DAB+ substrate chromogen system–
horseradish peroxidase used for immunocytochemistry was ob-
tained from Dako. Penicillin, streptomycin, RPMI 1640, and fetal
bovine serum (FBS) were obtained from Invitrogen. Tris, glycine,
NaCl, sodium dodecyl sulfate, and bovine serum albumin (BSA)
wereobtained from Sigma Chemical. Gemcitabine (Gemzar; kindly
supplied by Eli Lilly) was stored at 4uC and dissolved in sterile PBS
on the day of use.
Cell lines
The pancreatic cancer cell lines AsPC-1, BxPC-3, MIA PaCa-2,
and PANC-28 were obtained from American Type Culture
Collection. AsPC-1, PANC-28, BxPC3, and MIA PaCa-2 exhibit
K-Ras and p53 mutations, but BxPC-3 harbors wild-type K-Ras.
AsPC-1 and BxPC-3 cells were cultured in RPMI 1640
supplemented with 10% FBS, 100 units/mL penicillin, and
100 mg/mL streptomycin. MIA PaCa-2 was cultured in DMEM
supplemented with 12% FBS, and PANC-28 was cultured in
DMEM supplemented with 10% FBS, 100 units/mL penicillin,
and 100 mg/mL streptomycin.
Proliferation assay
The effect of AKBA on cell proliferation was determined by the
MTT uptake method as follows. The cells (2,000 per well) were
incubated with AKBA in triplicate in a 96-well plate and then
incubated for 2, 4, or 6 days at 37uC. An MTT solution was added
to each well and incubated for 2 hours at 37uC. An extraction
buffer (20% SDS and 50% dimethylformamide) was added, and
the cells were incubated overnight at 37uC. The absorbance of the
cell suspension was measured at 570 nm with an MRX Revelation
96-well multiscanner (Dynex Technologies).
Apoptosis assay
To determine whether AKBA potentiates the apoptotic effects
alone or in combination with gemcitabine in PaCa cells, we used a
LIVE/DEAD cell viability assay kit (Invitrogen), which measures
intracellular esterase activity and plasma membrane integrity. This
assay uses calcein, a polyanionic, green fluorescent dye that is
retained within live cells, and a red fluorescent ethidium
homodimer dye that can enter cells through damaged membranes
and bind to nucleic acids but is excluded by the intact plasma
membranes of live cells [42]. Briefly, cells (5,000 per well) were
incubated in chamber slides, pretreated with AKBA for 12 hours,
and treated with gemcitabine for 24 hours. Cells were then stained
with the assay reagents for 30 minutes at room temperature. Cell
viability was determined under a fluorescence microscope by
counting live (green) and dead (red) cells.
Animals
Male athymic nu/nu mice (4 weeks old) were obtained from the
breeding colony of the Department of Experimental Radiation
Oncology at University of Texas MD Anderson Cancer Center.
The animals were housed in standard Plexiglass cages (five per
cage) in a room maintained at constant temperature and humidity
and in a 12-hour light/12-hour dark cycle. Their diet consisted of
regular autoclave chow and water ad libitum. None of the mice
had any lesions, and all were tested pathogen free. Before initiating
Figure 6. HPLC chromatogram of AKBA in plasma (left) and PaCa tissue (right) in mice.
doi:10.1371/journal.pone.0026943.g006
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for 3 days. Our experimental protocol was reviewed and approved
by the Institutional Animal Care and Use Committee at University
of Texas MD Anderson Cancer Center.
Orthotopic implantation of pancreatic tumor cells
PANC-28 cells were stably transfected with luciferase as
previously described [43]. Luciferase-transfected PANC-28 cells
were harvested from subconfluent cultures after a brief exposure to
0.25% trypsin and 0.2% EDTA. Trypsinization was stopped with
medium containing 10% FBS. The cells were washed once in
serum-free medium and resuspended in PBS. Only suspensions
consisting of single cells, with .90% viability, were used for the
injections. After mice were anesthetized with ketamine-xylazine
solution, a small incision was made in the left abdominal flank,
and PANC-28 cells (1610
6) in 100 mL PBS were injected into the
subcapsular region of the pancreas with a 27-gauge needle and a
calibrated push button–controlled dispensing device (Hamilton
Syringe Co.). A cotton swab was held cautiously for 1 minute over
the site of injection to prevent leakage. The abdominal wound was
closed in one layer with wound clips (Braintree Scientific, Inc.).
Experimental protocol
One week after implantation, the mice were randomized into
the following treatment groups (n=5 per group) based on the
bioluminescence first measured with an in vivo imaging system
(IVIS 200, Xenogen Corp.): (a) untreated control (corn oil, 100 mL
daily), (b) AKBA (100 mg/kg once daily p.o.), (c) gemcitabine
alone (25 mg/kg twice weekly by i.p. injection), and (d)
combination (AKBA, 100 mg/kg once daily p.o., and gemcita-
bine, 25 mg/kg twice weekly by i.p. injection). Tumor volumes
were monitored weekly with the bioluminescence IVIS, which
includes a cryogenic cooling unit, and a data acquisition computer
running Living Image software (Xenogen Corp.). Before imaging,
the animals were anesthetized in an acrylic chamber with 2.5%
isoflurane/air mixture and injected i.p. with 40 mg/mL d-luciferin
potassium salt in PBS at a dose of 150 mg/kg body weight. After
10 minutes of incubation with luciferin, each mouse was placed in
a right lateral decubitus position and a digital grayscale animal
image was acquired, followed by the acquisition and overlay of a
pseudocolor image representing the spatial distribution of detected
photons emerging from active luciferase within the animal. Signal
intensity was quantified as the sum of all detected photons within
the region of interest per second. The mice were subjected to
imaging on days 0, 7, 14, 21, and 28 of treatment. Therapy was
continued for 4 weeks, and the animals were euthanized 1 week
later. Primary tumors in the pancreas were excised, and the final
tumor volume was measured as V=2/3pr
3, where r is the mean of
the three dimensions (length, width, and depth). Half of the tumor
tissue was fixed in formalin and embedded in paraffin for
immunohistochemistry and routine H&E staining. The other half
was snap frozen in liquid nitrogen and stored at 280uC. H&E
staining confirmed the presence of tumors in each pancreas.
Preparation of nuclear extract from tumor samples
Pancreatic tumor tissues (75–100 mg/mouse) from mice in the
control and treatment groups were minced and incubated on ice
for 30 minutes in 0.5 mL of ice-cold buffer A [10 mmol/L HEPES
(pH 7.9), 1.5 mmol/L KCl, 10 mmol/L MgCl2, 0.5 mmol/L
DTT, and 0.5 mmol/L phenylmethylsulfonyl fluoride (PMSF)].
The minced tissue was homogenized using a Dounce homogenizer
and centrifuged at 16,0006ga t4 uC for 10 minutes. The resulting
nuclear pellet was suspended in 0.2 mL of buffer B [20 mmol/L
HEPES (pH 7.9), 25% glycerol, 1.5 mmol/L MgCl2, 420 mmol/
L NaCl, 0.5 mmol/L DTT, 0.2 mmol/L EDTA, 0.5 mmol/L
PMSF, and 2 mg/mL leupeptin] and incubated on ice for 2 hours
with intermittent mixing. The suspension was then centrifuged at
16,0006ga t4 uC for 30 minutes. The supernatant (nuclear extract)
was collected and stored at 270uC until used. Protein concentra-
tion was measured by the Bradford assay with BSA as the
standard.
NF-kB activation in pancreatic cancer cells
To assess NF-kB activation, we isolated nuclei from pancreatic
cancer cell lines and tumor samples and carried out electropho-
retic mobility shift assays (EMSA) essentially as described next.
Briefly, nuclear extracts prepared from pancreatic cancer cells
(1610
6/mL) and tumor samples were incubated with
32P-end-
labeled 45-mer double-stranded NF-kB oligonucleotide (4 mg
of protein with 16 fmol of DNA) from the HIV long ter-
minal repeat (59-TTGTTACAAGGGACTTTCCGCTGGG-
GACTTTCCAGGGGGAGGCGTGG-39; boldface indicates
NF-kB–binding sites) for 15 minutes at 37uC. The resulting
DNA-protein complex was separated from free oligonucleotide on
6.6% native polyacrylamide gels. The dried gels were visualized,
and radioactive bands were quantitated with PhosphorImager and
ImageQuant software (GE Healthcare).
Immunohistochemistry of COX-2, MMP-9, CXCR4, and
VEGF in tumor samples
The expression of COX-2, MMP-9, CXCR4, and VEGF was
determined via an immunohistochemical method described
previously [44]. Briefly, pancreatic tumor samples were embedded
in paraffin and fixed with paraformaldehyde. After being washed
in PBS, the slides were blocked with protein block solution (Dako)
for 20 minutes and then incubated overnight with rabbit
polyclonal anti-human CXCR4 and anti-MMP-9 (1:100 for each)
or mouse monoclonal anti-human VEGF and anti-COX-2
antibodies (1:50 and 1:75, respectively). After incubation with
the antibodies, the slides were washed and then incubated with
biotinylated link universal antiserum followed by horseradish
peroxidase-streptavidin detection with the LSAB+ kit (Dako). The
slides were rinsed, and color was developed with 3,39-diamino-
benzidine hydrochloride used as a chromogen. Finally, sections
were rinsed in distilled water, counterstained with Mayer’s
hematoxylin, and mounted with DPX mounting medium (Sigma)
for evaluation. Pictures were captured with a Photometrics
CoolSNAP CF color camera (Nikon) and MetaMorph software
version 4.6.5 (Universal Imaging).
Ki-67 immunohistochemistry
Formalin-fixed, paraffin-embedded sections (5 mm) were stained
with anti-Ki-67 (rabbit monoclonal clone SP6) antibody as described
previously [42]. Results were expressed as the percentage of Ki-67
positive 6 SEM per 406magnification. A total of ten 406fields
were examined and stained cells were counted in three tumors from
each of the treatment groups.
CD31 immunohistochemistry
Ethanol-fixed, paraffin-embedded sections (5 mm) were stained
with rat anti-mouse CD31 monoclonal antibodies. Areas of highest
microvessel density were then examined under high magnification
(1006) and counted. Any distinct area of positive staining for
CD31 was counted as a single vessel. Results were expressed as the
mean number of vessels 6 SEM per high power field (1006
magnification). Twenty high-power fields were examined and
counted for each of three tumors from each treatment group.
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Pancreatic tumor tissues (75–100 mg/mouse) from mice in the
control and treatment groups were minced and incubated on ice
for 30 minutes in 0.5 mL of ice-cold whole-cell lysate buffer (10%
NP40, 5 mol/L NaCl, 1 mol/L HEPES, 0.1 mol/L EGTA,
0.5 mol/L EDTA, 0.1 mol/L PMSF, 0.2 mol/L sodium ortho-
vanadate, 1 mol/L NaF, 2 mg/mL aprotinin, and 2 mg/mL
leupeptin). The minced tissue was homogenized with a Dounce
homogenizer and centrifuged at 16,0006ga t4 uC for 10 minutes.
The proteins were then fractionated by SDS-PAGE, electrotrans-
ferred to nitrocellulose membranes, blotted with each antibody,
and detected by enhanced chemiluminescence reagents (GE
Healthcare).
Measurement of serum and tissue levels of AKBA
AKBA was determined by reverse-phase high performance
liquid chromatography (HPLC) on a high-pressure chromato-
graph equipped with an ultraviolet detector and a 2.06150-mm
column (Gemini C18; particle size, 5 mm, 110A0). The column
was eluted in an isocratic flow with a component acetonitrile:-
methanol:acetic acid (1%) ratio of 70:20:10 at an eluent flow rate
of 0.35 mL/min. The sample volume was 10 mL. The target
compounds were detected at 250 nM. The solution components
were identified and quantitatively analyzed using the external
standard method with linear regression equations, reliability of
approximation (R2), and detection thresholds for AKBA by
HPLC. The blood samples were taken from animals 4 h after the
administration of AKBA or vehicle. The samples were centrifuged
for 20 min at 2000 rpm to obtain the blood plasma, treated with
acetone (1.5:1) for deproteination, and centrifuged again for
15 min at 3000 rpm. The supernatant fraction was separated and
extracted with chloroform (2:1). The chloroform extract was
separated, the solvent was removed, and the dry residue was
dissolved in methanol and analyzed by HPLC.
Statistics
In vitro experiments were repeated twice, and statistical analysis
was performed. The values were initially subjected to one-way
ANOVA, which revealed significant differences between groups,
and then later compared between groups with an unpaired
Student’s t test, which revealed significant differences between two
sample means. In vivo experiments were done as at least three
independent assays. The values were initially subjected to one-way
ANOVA and then later compared among groups with an
unpaired Student’s t test.
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